Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT06056310
Title Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors EMD Serono Research & Development Institute, Inc.
Age Groups: adult | senior
Covered Countries USA | ESP | BEL

No variant requirements are available.